Valuing Biodiversity for Use in Pharmaceutical Research
R David Simpson,
Roger Sedjo () and
John W Reid
Journal of Political Economy, 1996, vol. 104, issue 1, 163-85
'Biodiversity prospecting' has been touted as a mechanism for both discovering new pharmaceutical products and saving endangered ecosystems. It is unclear what values may arise from such activities, however. Evidence from transactions is incomplete and existing theoretical models are flawed. The authors calculate an upper bound on the value of the 'marginal species.' Even under favorable assumptions this bound is modest. Slightly modified assumptions lead to drastically lower estimates. The authors extend their findings to the value of the marginal hectare of habitat and find that the incentives for habitat conservation generated by private pharmaceutical research are also, at best, very modest. Copyright 1996 by University of Chicago Press.
References: View complete reference list from CitEc
Citations View citations in EconPapers (113) Track citations by RSS feed
Downloads: (external link)
http://dx.doi.org/10.1086/262021 full text (application/pdf)
Access to full text is restricted to subscribers. See http://www.journals.uchicago.edu/JPE for details.
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:ucp:jpolec:v:104:y:1996:i:1:p:163-85
Access Statistics for this article
More articles in Journal of Political Economy from University of Chicago Press
Bibliographic data for series maintained by Journals Division ().